Reimagining the way substance use disorders are treated by developing novel, best-in-class therapeutics.

Anebulo is developing innovative, life-saving therapies that will improve the lives of millions of patients struggling with substance use disorders.

Learn more about us
Latest News

Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid Intoxication

Welcome to Anebulo Pharmaceuticals

We are focused on developing best-in-class therapeutic solutions for substance use disorders with high unmet medical needs, such as cannabinoid intoxication and various addiction indications.

Legalization map

Drivers of the Increasing Incidence of Cannabis Intoxication

Cannabis is now legal for recreational use in 11 states and legal for medical use in 33 states, and more states are likely to legalize cannabis over time. Legalization has not only increased habitual cannabis use, but has also served as a driver for increasing emergency room visits due to cannabinoid intoxication, with ingestion of edible and synthetic products being the leading concern.

Children are particularly vulnerable to intoxication given their lower body mass and lack of awareness. Edible cannabis products pose unique risk for pediatric exposure because of their brightly colored packaging and formulation into candies and other sweets. National Poison Data System call volumes show a 30% increase in pediatric related calls in states post-legalization.

Learn more
1M

There were an estimated 1.7 million cannabis-associated emergency room visits in 2019.

15%

The number of cannabis-associated emergency room visits is expected to grow at a 15% CAGR as more states legalize cannabis.

7

A physician survey showed that there is a very strong need for a cannabinoid antagonist to treat cannabis intoxication, with the average score being 7.52 on a scale of 0 (no need) to 10 (significant need), with several physicians noting they “can’t wait for an antidote”.

Pipeline

Given the rise in cannabis-associated emergency room visits and continuing expansion of cannabis legalization, there is an urgent need for a treatment to reverse the symptoms of cannabinoid intoxication.

Our pipeline

Our lead investigational therapeutic candidate is ANEB-001, a cannabinoid antagonist that reverses the effects of cannabinoid. We intend to begin a Phase 2 trial of ANEB-001 in 2021.

  • Products
  • Indication
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Marketed
  • ANEB-001
  • Cannabinoid Intoxication
  • Cannabinoid Intoxication
  • Cannabinoid Intoxication
  • Cannabinoid Intoxication